Between-sample variation in tracer binding in the 1251..
The radioimmunoassay for digoxin has become widely used as an aid in the care of patients receiving digoxin therapy.
There has, however, been a considerable amount of controversy regarding the value of information on serum digoxin concentrations in distinguishing toxic from nontoxic patients, as well as in determining a patient's therapeutic status (1) (2) (3) .
Problems with assay methodology may contribute to differences regarding the significance of serum concentrations.
The digoxin radioimmunoassay can be accomplished with use of either 3H or the 125! The 125J method is often used in clinical and research settings, primarily because there is no interference by quenching. As a result, much investigation has centered on the 125! assay. The relationship of albumin concentration to the binding of the 125J tracer has been studied (2, 4) . The variability of results obtained for different serum samples containing the same concentrations of digoxin has been shown (5) . One group of investigators has shown differences between standard curves prepared with use of different normal sera (6) .
Probably the most perplexing problem involved with the 125J method is the variation in the binding of the tracer and thus in the height and slope of the standard curves that are prepared in various normal sera. These "unknown plasma factors" (6) can result in errors when the serum used for the standard curve differs in nonspecific tracer binding effects from the samples. Two structurally different 1251-labeled digoxin derivatives are in use in the digoxin radioimmunoassay. The one most frequently present in commercial digoxin kits is 3-0-succinyl-digoxigenin-125I]tyrosine (SDT), in which iodinated succinyl-tyrosine is substituted for the three digitoxose sugars in the digoxin molecule. Recently, [1251J-labeled tyrosinemethyl-ester-digoxin (TME) has been used. Although the exact structure is in doubt, the ['25IJ-labeled tyrosinemethyl-ester is attached to the terminal digitoxose residue.
Thus, all sugars remain in place.
In this study, the variation in binding of the two digoxin derivatives with different normal sera was investigated as well as serum factors that could possibly produce errors in the results obtained with the 125J method.
Materials and Methods
Reagents. month and serum was then collected from the rabbit. Cross reactivity of the antiserum with 1000 jig/liter of various substances was as follows: progesterone (14%), 17 a-estradiol (5%), 17 -estradiol (3%), testosterone (<1%), cortisol (3%), and spironolactone (5%).
Procedures.
A 100-jil sample of serum was pipetted into a polystyrene tube, and 1 ml of the albumin-containing buffer and 50 jil of the radioactive digoxin derivative were added to the tube. Appropriate amounts of a solution of digoxin in ethanol/water (30/70 by vol) were used in the preparation of standards. The antiserum was diluted 110-fold with the albumin-containing buffer, 50 jil of the dilution was added to each tube, and the contents of the tubes were mixed on a vortex-type mixer and incubated at room temperature for 30 mm. Then 1 ml of the charcoal suspension was added, to separate bound from free molecules. (Charcoal adsorbed over 95% of the tracer when no antiserum was present.) After a 3-mm incubation the tubes were centrifuged at 3000 X g for 2 mm at 4#{176}C. The supernates were decanted into clean, plastic tubes, and both they and the charcoal were counted to allow estimation of total counts per tube. Counting was done in a Packard Auto-Gamma Scintillation Spectrometer, Model 5986 with multi-channel analyzer (Packard Instrument Co., Downers Grove, Ill. 60515) that enables counting from 0.020 to 0.042 meV.
For each sample, the percentage of the tracer bound by the antibody was calculated by dividing the counts in the supernatant fluid by the total counts in the original tube (counts in the supernate plus counts in the charcoal). Each sample was assayed in duplicate and means were calculated. Only those duplicates that differed by 3% from each other were acceptable.
Serum samples having a wide range (<10 to >200 jig/liter of thyroxine concentrations were studied. These samples were assayed according to the procedure described above and the percentage bound was determined for each. Patients' charts were examined, to avoid using samples that contained digoxin, The curves on each graph were prepared from the same two serum samples digitoxin, steroid drugs, or other drugs that were likely to cross-react with the antiserum. Serum samples were assayed by use of both the SDT and the TME derivatives.
To study the effects of changing thyroxine status while other factors were controlled, we injected beagle dogs intramuscularly on three consecutive days with jO mt.units of thyrotropin.
Blood samples were drawn two days before, immediately before, and 6 h after each injection, as well as on several days after the injections. The sera from these samples were then assayed to determine the percent of tracer bound to antibody, using the succinyl-digoxigenin-tyrosine derivative.
Results
Results of the assay with SDT of patients' sera with various thyroxine concentrations are shown in Figure 1 (top) . The samples have been grouped on the basis of thyroxine concentrations-low, medium, and high. The percentage bound for the low thyroxine group is significantly higher than that of the middle (P < 0.001) and that of the high (P <0.05) group. Figure 1 (bottom) shows the results for the same samples assayed under the same conditions with the TME derivative. There was no significant difference between the samples within a group or between groups.
We prepared standard curves from two serum samples that differed in percentage bound when assayed with the SDT derivative, to establish what differences in binding there would be between the two samples at various digoxin concentrations. Each serum sample was used to prepare two standard curves, one with use of the SDT derivative and one with use of the TME derivative. The curves, shown in Figure   2 , illustrate that standard curves with quite different slopes resulted when the SDT was used, but there was little difference between the standard curves produced with the TME derivative.
The sera from the dogs dosed with thyrotropin showed a mean change from baseline of -1.9 (±3.7 SD) in percentage 2) when assayed with the TME derivative. Significantly less variation occurred with the TME (P <0.005). The data for one of the dogsare illustrated in Figure 3 . Significant variation in percent bound is seen only when samples were assayed with use of the SDT derivative.
Discussion
Differences in the binding of the SDT tracer with different normal sera observed in this study are similar to those previously reported. It is unlikely that these discrepancies are related to lack of specificity of the antiserum used in the assay, especially since they are present only when the SDT derivative is used.
Nonspecific interference of serum components with the '251-labeled digoxmn radioimmunoassay appears to be eliminated with the use of the TME derivative in this assay. The slope as well as the height of the standard curve is related to the percent bound of the zero standard. Thus, determination of the percent of radiolabeled tracer bound to antibody in a serum sample with no digoxin present is both a convenient and a valuable tool in assessing the variation among standard curves prepared in different norma sera.
Inspection of the standard curves in Figure 2 would be assumed to be 0.8 ng/ml. These errors do not occur when TME tracer is used (bottom), because the standard curves are essentially the same.
Our studies show that thyroxine concentration may be related to variation in binding of the SDT tracer in the digoxmn radioimmunoassay. A possible explanation for this is that thyroxine is bound in the blood by specific proteins: thyroxine-binding globulin and thyroxine-binding prealbummn. These proteins may have a measurable effect on a derivative in which the radioactive iodine is bound to tyrosine, such as those used in the digoxmn radioimmunoassay. If these denyatives bind to the proteins or if their binding is enhanced by them, an apparent increase in the percentage bound would result. Thyroxine-binding proteins are less saturated at low concentrations of thyroxine and, as a result, their capacity for influencing the tracer binding may be increased (8) . At high serum thyroxine concentrations there appears to be less nonspecific binding of the tracer. This may be because the thyroxine-binding proteins are more nearly saturated. Variations in thyroid status may partially explain between-sample variations in tracer binding in the digoxin assay. When the dogs were dosed with thynotropin, there was an unmistakable influence on the binding of the SDT derivative. Occasional variations in binding of the SDT derivative before dosing with thyrotropin have been noted, but theseappear to be random occurrences. Evidently thyroid variations are complex, and more than one factor may be responsible for variable tracer binding.
Our data indicate that results vary when the SDT derivative is used in this assay system. Between-sample variation with this derivative may be related to factors affecting the nonspecific binding of the derivative, such as thyroxine status. The data obtained with the TME derivative, however, suggest little change in binding between samples. Although it is not clear why the binding of the TME derivative was consistent, we may speculate that because of its molecular configuration or the presence of the digitoxose sugars, less nonspecific binding occurred. The use of the TME derivative in the system described eliminates much of the between-sample variation associated with the digoxin radioimmunoassay, and, as a result, errors in estimating digoxin concentrations will be decreased.
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